Background: In the RV144 trial, human immunodeficiency virus (HIV)-1 gp120 V1V2 antibodies correlated inversely with risk of HIV-1 infection; however, the titers waned quickly. We hypothesized that a more potent adjuvant might enhance the magnitude and durability of V1V2 antibodies. Methods: We examined archived sera from a phase I randomized, double-blind placebo-controlled trial, conducted in HIV-1-uninfected individuals, vaccinated with HIV-1SF-2 rgp120 either adsorbed toaluminum hydroxide (aluminum hydroxide arm) or encapsulated in liposomes containing monophosphoryl lipid A (MPL®) and then adsorbed to aluminum hydroxide (liposomal arm). Results: The median immunoglobulin G antibody titers across weeks 10-112 were higher in the liposomal arm against subtypes B (2- to 16-fold), AE (4- to 8-fold), and C (4- to 16-fold) V1V2 proteins. High titers were maintained even at 10 months after last boost in the liposomal compared with the aluminum hydroxide arm. The antibodies exhibited antibody-dependent cellular cytotoxicity (ADCC) and α4β7-integrin receptor inhibition-binding functions. Conclusions: Inclusion of 2 adjuvants in the vaccine formulation, aluminum hydroxide, and liposomal MPL®, induced robust, durable, and functional antibodies. Based on the magnitude of antibody responses and the percentage of coiled and β-sheet in the predicted V2/V3-peptide structure, we speculate that liposomal gp120 was presented in a conformation that favored the induction of robust antibody responses.
RCT Entities:
Background: In the RV144 trial, human immunodeficiency virus (HIV)-1gp120 V1V2 antibodies correlated inversely with risk of HIV-1 infection; however, the titers waned quickly. We hypothesized that a more potent adjuvant might enhance the magnitude and durability of V1V2 antibodies. Methods: We examined archived sera from a phase I randomized, double-blind placebo-controlled trial, conducted in HIV-1-uninfected individuals, vaccinated with HIV-1SF-2 rgp120 either adsorbed to aluminum hydroxide (aluminum hydroxide arm) or encapsulated in liposomes containing monophosphoryl lipid A (MPL®) and then adsorbed to aluminum hydroxide (liposomal arm). Results: The median immunoglobulin G antibody titers across weeks 10-112 were higher in the liposomal arm against subtypes B (2- to 16-fold), AE (4- to 8-fold), and C (4- to 16-fold) V1V2 proteins. High titers were maintained even at 10 months after last boost in the liposomal compared with the aluminum hydroxide arm. The antibodies exhibited antibody-dependent cellular cytotoxicity (ADCC) and α4β7-integrin receptor inhibition-binding functions. Conclusions: Inclusion of 2 adjuvants in the vaccine formulation, aluminum hydroxide, and liposomal MPL®, induced robust, durable, and functional antibodies. Based on the magnitude of antibody responses and the percentage of coiled and β-sheet in the predicted V2/V3-peptide structure, we speculate that liposomal gp120 was presented in a conformation that favored the induction of robust antibody responses.
Authors: Carl R Alving; Kristina K Peachman; Gary R Matyas; Mangala Rao; Zoltan Beck Journal: Expert Rev Vaccines Date: 2020-03-31 Impact factor: 5.217
Authors: Hung V Trinh; Neelakshi Gohain; Peter T Pham; Christopher Hamlin; Hongshuo Song; Eric Sanders-Buell; Meera Bose; Leigh A Eller; Swati Jain; Gherman Uritskiy; Venigalla B Rao; Sodsai Tovanabutra; Nelson L Michael; Merlin L Robb; M Gordon Joyce; Mangala Rao Journal: Cells Date: 2019-04-19 Impact factor: 6.600
Authors: Shiwei Xu; Margaret C Carpenter; Rachel L Spreng; Scott D Neidich; Sharanya Sarkar; DeAnna Tenney; Derrick Goodman; Sheetal Sawant; Shalini Jha; Brooke Dunn; M Juliana McElrath; Valerie Bekker; Sarah V Mudrak; Robin Flinko; George K Lewis; Guido Ferrari; Georgia D Tomaras; Xiaoying Shen; Margaret E Ackerman Journal: NPJ Vaccines Date: 2022-08-04 Impact factor: 9.399
Authors: Daniela P Lage; Patrícia A F Ribeiro; Daniel S Dias; Débora V C Mendonça; Fernanda F Ramos; Lívia M Carvalho; Bethina T Steiner; Grasiele S V Tavares; Vívian T Martins; Amanda S Machado; João A Oliveira-da-Silva; Thaís T O Santos; Camila S Freitas; Jamil S Oliveira; Bruno M Roatt; Ricardo A Machado-de-Ávila; Maria V Humbert; Myron Christodoulides; Eduardo A F Coelho Journal: Vaccines (Basel) Date: 2020-06-09